KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
European Journal of Cancer2006Vol. 42(8), pp. 1093–1103
Citations Over TimeTop 1% of 2006 papers
Maria Dêbiec‐Rychter, Raf Sciot, Axel Le Cesne, M. Schlemmer, Peter Hohenberger, Allan T. van Oosterom, Jean‐Yves Blay, Serge Leyvraz, Michel Stul, Paolo G. Casali, John Zalcberg, Jaap Verweij, M. van Glabbeke, Anne Hagemeijer, Ian Judson
Related Papers
- → The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST)(2017)65 cited
- → A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients(2011)53 cited
- → Molecular biomarkers for prognosis of gastrointestinal stromal tumor(2018)34 cited
- → Diagnosis value of CD117 and PDGFRA, alone or in combination DOG1, as biomarkers for gastrointestinal stromal tumors.(2015)14 cited
- → [Characteristics and targeted therapy of wild-type gastrointestinal stromal tumor].(2020)